-The Hindu     Questioning a technology, especially of the kind that has serious unknowns and lacks clear social benefits, is not an attack on science Jairam Ramesh, former Environment Minister for India, made the brave decision in 2010 to tell his then apex regulator of genetically modified organisms (GEAC) that it had failed to properly use available science to determine the safety - to human health and the environment - of Bt brinjal,...

-The Hindustan Times After the political parties, now the Department of Atomic Energy has asked the government to keep it out of the Right to Information Act, saying the transparency law is in conflict with its international commitments which require "strict confidentiality." However, the DAE's demand for immediate exemption from the RTI Act through an official notification is unlikely to be accepted with the law ministry raising a red flag, citing the...

-The Economic Times CHENNAI: India's patent appeals board has denied Monsanto a patent for a genetically-engineered method of increasing climate resilience in plants. The decision is significant not only for Monsanto's loss of possible exclusivity in an increasingly important segment but also for the interpretation of India's home-grown clauses in patent law - these are unpopular with global companies - for the first time in the case of plants. The Intellectual Property...

-PTI India however maintained that the India Patent Act was in accordance with the TRIPS Agreement & the Paris Convention The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains concerned about the deteriorating intellectual property environment in India," Mark Grayson, PhRMA spokesman told PTI. The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's...

-The Business Standard Angelina Jolie has inadvertently highlighted a key question about patenting Angelina Jolies recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US...